results
Last reviewed 01/2018
The benefits of interferon beta-1a treatment included:
- reduction in relapse rates:
- 27% for the 22 mcg group
- 33% for the 44 mcg group
- prolongation in the time to first relapse:
- 3 months for the 22 mcg group
- 5 months for the 44 mcg group
- time to sustained progression was significantly longer in both treatment groups (p<0.05)
- disease burden as assessed by T2-weighted MRI scans was significantly lower in both treatment groups